Matsuda Hiroshi, Yamao Tensho, Shakado Mitsuru, Shigemoto Yoko, Okita Kyoji, Sato Noriko
Department of Biofunctional Imaging, Fukushima Medical University, 1 Hikariga-oka, Fukushima City, Fukushima, 960-1295, Japan.
Drug Discovery and Cyclotron Research Center, Southern Tohoku Research Institute for Neuroscience, 7-61-2 Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan.
EJNMMI Res. 2021 Dec 14;11(1):125. doi: 10.1186/s13550-021-00867-7.
Centiloid (CL) scaling has become a standardized quantitative measure in amyloid PET because it facilitates the direct comparison of results across institutions, even when different analytical methods or tracers are used. Standard volumes of interest must be used to calculate the CL scale after the anatomic standardization of amyloid PET images using coregistered MRI; if the MRI is unavailable, the CL scale cannot be accurately calculated. This study sought to determine the substitutability of low-dose CT, which is used to correct PET attenuation in PET/CT equipment, by evaluating the measurement accuracy when low-dose CT is used as an alternative to MRI in the calculation of the CL scale. Amyloid PET images obtained using F-flutemetamol from 24 patients with possible or probable Alzheimer's disease were processed to calculate the CL scale using 3D T1-weighted MRI and low-dose CT of PET/CT. CL and CL were, respectively, defined as the use of MRI and CT for anatomic standardization and compared. Regional differences in the CT-based and MRI-based standardized anatomic images were also investigated.
Japan Registry of Clinical Trials, jRCTs031180321 (registered 18 March 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031180321 ).
A Bland-Altman plot showed that CL was slightly but significantly underestimated (mean ± standard deviation, - 1.7 ± 2.4; p < 0.002) compared with CL. The 95% limits of agreement ranged from - 2.8 to - 0.7. Pearson correlation analysis showed a highly significant correlation of r = 0.998 between CL and CL (p < 0.001). The linear regression equation was CL = 1.027 × CL + 0.762. In a Bland-Altman plot, Spearman correlation analysis did not identify a significant association between the difference in CL versus CL and CL load (ρ = - 0.389, p = 0.060). This slight underestimation of CL may derive from slightly higher uptake when the cerebellum is used as a reference area in CT-based anatomically standardized PET images versus MRI-based images.
Low-dose CT of PET/CT can substitute for MRI in the anatomic standardization used to calculate the CL scale from amyloid PET, although a slight underestimation occurs.
百分克分子(CL)标度已成为淀粉样蛋白PET中的一种标准化定量测量方法,因为它有助于跨机构直接比较结果,即使使用不同的分析方法或示踪剂。在使用配准MRI对淀粉样蛋白PET图像进行解剖标准化后,必须使用标准感兴趣体积来计算CL标度;如果无法获得MRI,则无法准确计算CL标度。本研究旨在通过评估在计算CL标度时使用低剂量CT替代MRI的测量准确性,来确定用于PET/CT设备中校正PET衰减的低剂量CT的可替代性。对24例可能或疑似阿尔茨海默病患者使用F-氟代甲硫氨酸获得的淀粉样蛋白PET图像进行处理,以使用3D T1加权MRI和PET/CT的低剂量CT计算CL标度。CL和CL分别定义为使用MRI和CT进行解剖标准化,并进行比较。还研究了基于CT和基于MRI的标准化解剖图像的区域差异。
日本临床试验注册中心,jRCTs031180321(2019年3月18日注册,https://jrct.niph.go.jp/latest-detail/jRCTs031180321)。
Bland-Altman图显示,与CL相比,CL略有但显著低估(平均值±标准差,-1.7±2.4;p<0.002)。95%一致性界限为-2.8至-0.7。Pearson相关分析显示CL与CL之间的相关性非常显著,r=0.998(p<0.001)。线性回归方程为CL=1.027×CL+0.762。在Bland-Altman图中,Spearman相关分析未发现CL与CL的差异与CL负荷之间存在显著关联(ρ=-0.389,p=0.060)。CL的这种轻微低估可能源于在基于CT的解剖标准化PET图像中与基于MRI的图像相比,当将小脑用作参考区域时摄取略高。
PET/CT的低剂量CT可替代MRI用于从淀粉样蛋白PET计算CL标度的解剖标准化,尽管会出现轻微低估。